Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AWAKE-HF: Sacubitril/Valsartan vs Enalapril on Activity/Sleep in HFrEF
NCT02970669Phase 4Completed
- Sponsor
- Novartis
- Start
- Dec 2016
- Primary completion
- Mar 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of sacubitril + valsartan in heart failure with reduced ejection fraction (HFrEF) (2 arms), sponsored by Novartis. Primary endpoint: Ratio of Mean Activity Counts During the Most Active 30 Minutes of the Subject's Day at 8 weeks. Started Dec 2016; status: completed.
02
Drugs
sacubitril + valsartan
03
Conditions
heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on NCT02970669.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02970669.